Assessment of DNA oxidation and antioxidant activity in hypertensive patients with chronic kidney disease

Renal Failure

Volumn 30, Issue 10, 2008, Pages 1006-1011

  Dincer, Yildiz ^a,b   Sekercioglu, Nigar ^a   Pekpak, Meltem ^a   Gunes, Kezban N ^a   Akcay, Tulay ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Angiotensin converting enzyme inhibitor; Blood pressure; Calcium channel blocker; Glutathione peroxidase; Kidney function; Markers of oxidative stress; Superoxide dismutase

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUTATHIONE PEROXIDASE; SUPEROXIDE DISMUTASE;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ANTIOXIDANT ACTIVITY; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE MARKER; DNA DAMAGE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; PROTEINURIA; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; DEOXYGUANOSINE; DNA DAMAGE; FEMALE; GLUTATHIONE PEROXIDASE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OXIDATIVE STRESS; SUPEROXIDE DISMUTASE; YOUNG ADULT;

EID: 57049183130     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220802422044     Document Type: Article

References (33)

1. Halliwell B, Gutteridge JMC. Antioxidant defences. In: Halliwell B, Gutteridge JMC, eds. Free radicals in biology and medicine. Oxford: Oxford University Press; 1996:107-146.
2. Rush JW, Sandiford SD. Plasma glutathione peroxidase in healthy young adults: Influence of gender and physical activity. Clin Biochem 2003;36(5):345-351.
3. Herta JM, Gonzalez S, Fernandez S, Patterson AM, Lasheras C. No evidence for oxidative stress as a mechanism of action of hyperhomocysteinemia in humans. Free Radical Res. 2004;8(11):1215-1221.
4. Cheng KC, Cahil DS, Kasai H, Nishimura S, Loeb LA. 8-Hydroxyguanine an abundant form of oxidative DNA damage, causes G→T and A→C substitutions. J Biol Chem. 1992;267:166-172.
5. Loft S, Poulsan HE. Cancer risk and oxidative damage in man. J Mol Med. 1996;74(6):297-312.
6. Mastalerz-Migas A, Steciwko A, Pokorski M, et al. What influences the level of oxidative stress as measured by 8-hydroxy-2′-deoxyguanosine in patients on hemodialysis? J Physiol Pharmacol. 2006;57 (Suppl):199-205.
7. Domenici FA, Vannucchi MT, Jordao AA Jr, Meirelles MS, Vannucchi H. DNA oxidative damage in patients with dialysis treatment. Ren Fail. 2005;27:689-694.
8. Olszewska M. The effect of hemodialysis on some parameters of the antioxidant system in the blood of patients with chronic renal failure. Ann Acad Med Stetin. 2004;50:41-52.
9. Tanaka M, Umemoto S, Kawahara S, et al. Angiotensin II type 1 receptor antagonist and angiotensin-converting enzyme inhibitor altered the activation of Cu/Zn-containing superoxide dismutase in the heart of stroke-prone spontaneously hypertensive rats. Hypertens Res. 2005;28:67-77.
10. Tandon R, Sinha MK, Garg H, Khanna R, Khanna HD. Oxidative stress in patients with essential hypertension. Natl Med J India. 2005;18:297-299.
11. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol. 2005;25:29-38.
12. Das UN. Angiotensin II behaves as an endogenous proinflammatory molecule. J Assoc Physicians India. 2005; 53: 472-476.
13. Cohuet G, Struijker-Boudier H. Mechanisms of target organ damage caused by hypertension: Therapeutic potential. Pharmacol Ter. 2006;111:81-98.
14. Ogawa S, Mori T, Nako K, Kato T, Takeuchi K, Ito S. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy. Hypertension. 2006;47:699-705.
15. Lazzaro A, Gallego-Delgado J, Justo P, et al. Long-term blood pressure control prevents oxidative renal injury. Antioxid Redox Signal. 2005;7:1285-1293.
16. Mori T, Cowley AW, Ito S. Molecular mechanisms and therapeutic strategies of chronic renal injury: Physiological role of angiotensin II-induced oxidative stress in renal medulla. J Pharmacol Sci. 2006;100:2-8.
17. Karalliedde J, Viberti G. Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes. J Hum Hypertens. 2006; 20(4): 239-253.
18. Weiss D, Sorescu D, Taylor R. Angiotensin II and atherosclerosis. Am J Cardiol. 2001;87:25c-32c.
19. Zalba G, San Jose G, Moreno MU, et al. Oxidative stress in arterial hypertension: Role of NAD(P)H oxidase. Hypertension 2001;38:1395-1399.
20. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-1923.
21. Baykal Y, Yilmaz MI, Celik T, et al. Effects of antihypertensive agents, alpha receptor blockers, beta blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and calcium channel blockers, on oxidative stress. J Hypertens. 2003;21:1207-1211.
22. Agarwal R. Proinflammatory effects of oxidative stress in chronic kidney disease: Role of additional angiotensin II blockade. Am J Physiol Renal Physiol. 2003;284:F863-F869.
23. Saez GT, Tormos C, Giner V, Chaves J, Lozano JV, et al. Factors related to the impact of antihypertensive treatment in antioxidant activities and oxidative stress by-products in human hypertension. Am J Hypertens. 2004;17:809-816.
24. Zachara BA, Trafikowska U, Adamowicz A, Nartowicz E, Manitius J. Selenium, glutathione peroxidases, and some other antioxidant parameters in blood of patients with chronic renal failure. J Trace Elem Med Biol. 2001;15:161-166.
25. Yoshimura S, Suemizu H, Nomoto Y, et al. Plasma glutathione peroxidase deficiency caused by renal dysfunction. Nephron. 1996;73:207-211.
26. Van Den Branden C, Ceyssens B, De Craemer D, et al. Antioxidant enzyme gene expression in rats with remnant kidney induced chronic renal failure. Exp Nephrol. 2000;8:91-96.
27. Vaziri ND, Dicus M, Ho ND, Boroujerdi-Rad L, Sindhu RK. Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int. 2003;63:179-185.
28. Kedziora-Kornatowska K, Szram S, Kornatowski T, Szadurski L, Kedziora J, Bartosz G. The effect of verapamil on the antioxidant defence system in diabetic kidney. Clin Chim Acta. 2002;322:105-112.
29. Okamoto K, Maruyama T, Kaji Y, et al.Verapamil prevents impairment in filterability of human erythrocytes exposed to oxidative stress. Jpn J Physiol. 2004;54:39-46.
30. Godfraind T. Antioxidant effects and the therapeutic mode of action of calcium channel blockers in hypertension and atherosclerosis. Philos Trans R Soc Lond B Biol Sci. 2005;360:2259-2272.
31. Mason RP. Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: Review of the evidence. Atherosclerosis. 2002;165:191-199.
32. Umemoto S, Tanaka M, Kawahara S, et al. Calcium antagonist reduces oxidative stress by upregulating Cu/Zn superoxide dismutase in stroke-prone spontaneously hypertensive rats. Hypertens Res. 2004;27:877-885.
33. Mimic-Oka J, Simic T, Djukanovic L, Reljic Z, Davicevic Z. Alteration in plasma antioxidant capacity in various degrees of chronic renal failure. Clin Nephrol. 1999;51:233-241.